CJC-1295 with DAC
DAC:GRF · Drug Affinity Complex CJC-1295
Popular for:Long-acting GH elevation, less frequent dosing, sustained IGF-1 increase
1
Registered Trials
2
Trial Publications
29
PubMed References
Phase II
Evidence Level
Overview
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone analog that binds to albumin in the bloodstream, extending its half-life from ~30 minutes (without DAC) to 6-8 days. The short version: people usually care about it for long-acting gh elevation, less frequent dosing, sustained igf-1 increase, but the strength of the evidence depends heavily on indication and study type.
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing hormone analog that binds to albumin in the bloodstream, extending its half-life from ~30 minutes (without DAC) to 6-8 days. This allows for once or twice weekly dosing instead of multiple daily injections.
The DAC modification fundamentally changes the pharmacokinetics — instead of producing acute GH pulses like standard CJC-1295 (Mod GRF 1-29), the DAC version creates sustained, elevated GH levels. This difference is significant: pulsatile release mimics natural physiology, while sustained elevation does not. Researchers debate which approach is preferable.
Research Snapshot
What the evidence says
Phase IICJC-1295 with DAC currently shows 1 registered trials from ClinicalTrials.gov, 2 PubMed trial publications (1 RCT-tagged), and 29 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.
Known vs uncertain
Known signals
- 1 registered trials are tracked from ClinicalTrials.gov intervention records.
- 2 PubMed clinical-trial publications are indexed.
- 1 PubMed randomized controlled trial publications are indexed.
- 29 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.
Open questions
- Evidence strength may vary by indication, route, formulation, and population.
- Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
- Regulatory status and compounding access can change independently from the research literature.
Mechanism of Action
The DAC moiety is a lysine linker with a maleimidopropionic acid group that covalently bonds to albumin after injection.
Key Research Benefits
Clinical Evidence Summary
Research Pipeline
1
Registered Trials
2
Trial Publications
1
RCT Publications
29
PubMed References
Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.
1
Registered trials
2
Trial publications
1
RCT publications
29
PubMed references
6
Reviews
0
Meta-analyses
Registered trials source
Jun 1, 2026
CJC-1295
Uses curated ClinicalTrials.gov intervention aliases to avoid misleading registry matches.
View sourcePublication counts source
May 3, 2026
CJC-1295
Uses the core CJC-1295 term because PubMed rarely writes the display label with DAC.
View sourceNot FDA-approved. Was in clinical trials by ConjuChem Biotechnologies. Research compound. Often compared unfavorably to non-DAC version due to non-pulsatile release pattern.
Key PubMed References
29 PubMed references · showing top 25 by relevance
View all on PubMedInjectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Mayfield CK, Bolia IK, Feingold CL, et al. · The American journal of sports medicine · 2026
PMID: 41476424Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
Mavrych V, Shypilova I, Bolgova O · Frontiers in aging · 2026
PMID: 42021992Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026
PMID: 41966639Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026
PMID: 41490200Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.
Thomas A, Walpurgis K, Thevis M · Journal of mass spectrometry : JMS · 2024
PMID: 38197510Anecdotes & Sentiment
This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.
No curated public-discussion themes are live for CJC-1295 with DAC yet.
Side Effects & Safety
- Water retention and bloating (more than non-DAC version) - Headache - Flushing - Potential for GH-related side effects from sustained elevation (joint pain, carpal tunnel) - Less physiological than pulsatile release — continuous GH elevat
Known Interactions
No curated interaction entry is live for CJC-1295 with DAC yet.
Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.
Comparison Pages
Comparison pages
AllNo comparison page is linked yet.
Frequently Asked Questions
Research Disclaimer
This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.